XML 20 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring Charges (Notes)
 3 Months Ended
Mar. 31, 2017
Restructuring Charges [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
Restructuring Charges

During the three months ended March 31, 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 3: Acquisitions and Strategic Transaction Expenses). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. We expect to complete these restructuring activities by the end of 2017. We estimate that we will incur additional charges in regard to these restructuring activities in the range of $2.7 million to $3.2 million.

During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.

The following table summarizes the details of changes in our restructuring-related accrual for the period ending March 31, 2017 (in thousands):

 
Accrued Balance December 31, 2016
 
Charges
Incurred
 
Payments
 
Other Adjustments
 
Accrued Balance
March 31,
 2017
Severance pay and benefits
$
53

 
$
6,211

 
$
(2,470
)
 
$
(17
)
 
$
3,777

Employment agreement buyout
1,477

 
—

 
(93
)
 
—

 
1,384

Facility closure expenses
—

 
2,103

 
(2,103
)
 
—

 
—

 
$
1,530

 
$
8,314

 
$
(4,666
)
 
$
(17
)
 
$
5,161